

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME <b>Lolie C. Yu, MD</b>	POSITION TITLE Eugenie & Joseph Jones Professor of Pediatric Oncology Division Chief, Director, Bone Marrow Transplant Program
eRA COMMONS USER NAME (credential, e.g., agency login)  LolieYu	

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Santo Tomas, Sampaloc, Manila	B.S.	1975	Psychology
University of Santo Tomas, Sampaloc, Manila	M.D.	1979	Medicine
University of Texas, Austin, Texas	Masters	1982	Public Health
Louisiana State University Health Sciences Center, New Orleans, Louisiana	Residency	1985	Pediatrics
Louisiana State University Health Sciences Center, New Orleans, Louisiana	Fellowship	1988	Pediatric Hem/Onc
Fred Hutchinson Cancer Research Center, Seattle, WA	Fellowship	1988	Bone Marrow Transplant

**A. Personal Statement**

I am a Professor of Pediatrics and a Pediatric Specialist in Hematology/Oncology at Louisiana State University Health Sciences Center and Children’s Hospital of New Orleans (CHNOLA), respectively. I direct the Bone Marrow Transplant Program and serve as the Director of the Autologous Bone Marrow Laboratory at CHNOLA. I work in the clinical research area and I am intimately involved with clinical trials, especially with the Children Oncology Group, with whom I am the COG PI. My areas of interest lie primarily in hematopoietic stem cell transplantation and the role of dendritic cells in improving immune function post-transplant. Since 2004, I have been actively involved in the LSUHSC MBCCOP as the COG PI.

**B. Positions and Honors**

- First Honors (High School)
- Cum Laude (Bachelor of Science, Major in Psychology)
- Meritus (Doctor of Medicine)
- Outstanding Pediatric Resident (1982-1985)
- Distinguished Woman Physician Award (1998-1999)
- Spirit of Love Award sponsored by Ronald McDonald (2004)
- Spirit Award Honoree 2010 by American Cancer Society

**Positions and Employment**

- 7/1/88-6/30/94     Assistant Professor of Pediatrics, LSU  
Department of Pediatrics, Section of Hematology/Oncology  
Children’s Hospital of New Orleans, LA
  
- 5/1/91-Present     Director, Bone Marrow Transplant Program  
Department of Pediatrics, LSUHSC, New Orleans, LA  
Children’s Hospital, New Orleans, LA
  
- 7/1/94-2002        Associate Professor of Pediatrics, LSUHSC  
Section of Hematology/Oncology  
Children’s Hospital, New Orleans, LA

- 7/1/02-Present Professor of Pediatrics, LSUHSC  
Section of Hematology/Oncology  
Children's Hospital, New Orleans, LA
- 2004 – Present Principal Investigator  
Children's Oncology group  
LSU-MBCCOP/Children's Hospital
- 4/15/07-Present Division Chief  
Section of Hematology/Oncology  
Children's Hospital/LSUHSC, New Orleans, LA

#### **Other Experience and Professional Memberships**

Member, Alpha Omega Alpha Honor Society  
Member, Greater New Orleans Pediatric Society  
Member, Louisiana State Medical Society  
Member, Orleans Parish Medical Society  
Member, American Society of Pediatric Hematology/Oncology  
Member, Children Oncology Group Member  
Member, American Society of Hematology  
Member, Southern Society of Pediatric Research  
Member, American Society for Blood and Marrow Transplantation

#### **C. Selected Peer-reviewed Publications**

1. **Yu L**, Shaneyfelt T, Warrierr RP, Ode D. The Efficacy of Ticarcillin/Clavulanate and Gentamicin as Empiric Treatment of Febrile Neutropenic Pediatric Patients with Cancer. *Pediatr Hematol Oncol* 1994; 11: 171-177.
2. **Yu L**, Kuvibidila S, Warrierr RP, Ducos R. Nutritional Status of Children with Leukemia. *Med Pediatr Oncol* 1994; 22:73-77.
3. Mahoney D, Strother D, Camitta B, Bowen T, Ghim T, Pick T, Wall D, **Yu L**, Shuster J, Friedman H. High Dose Melphalan and Cyclophosphamide with Autologous Bone Marrow Rescue for Recurrent/Progressive Malignant Brain Tumors in Children: A Pilot Pediatric Oncology Group Study. *J Clin Oncol* 1996; 14(2): 382-388.
4. Rocha V, Wagner J, Sobocinski K, Klein J et al **Yu LC**. Comparison of Graft versus Host Disease in Children transplanted with HLA-identical Sibling umbilical Cord Blood versus Bone Marrow Hematopoietic Stem Cells. *N Engl J Med* 2000, 342(25): 1846-1854.
5. **Yu L C**, Wall D, Sandler E, Chan KW, Grayson G, Kletzel M. Unrelated Cord Blood Transplant Experience by the Pediatric Blood and Marrow Transplant Consortium. *Pediatr Hematol/Oncol* 2001, 18:235-245.
6. Kuvibidila S, **Yu L**, Ode D, Velez M, Gardner R, Warrierr R. Effects of Iron Deficiency on the Secretion of interleukin-10 by mitogen-activated and non-activated murine spleen cells. *J Cellular Biochem* 2003; 90: 278-286.
7. Somjee S, **Yu LC**, Hagar A, Hempe J. Diagnosis and Characterization of Hb C/Hb Iowa: A rare but easily misidentified compound Heteroygous condition. *Hemoglobin* 2004; 28 (1); 7-13.
8. Godder K, Eapen M, Laver J, et al **Yu LC**. Autologous Hematopoietic Stem Cell Transplantation for Children with Acute Myeloid Leukemia in first or second complete remission: A prognostic factor analysis. *J Clin Oncol* 2004; 15:22(18): 3798-3804.
9. Shenoy S, Grossman WJ, Dipersio J, **Yu LC**, et al. A novel reduced-intensity stem cell transplant for Non-malignant disorders. *Bone Marrow Transplant* 2005; 35(4); 345-352.

10. Occhipinti E, Correa H, **Yu L**, Craver RD. Inclusion of secondary Chronic Myelomonocytic leukemia and Myeloproliferative Disease, Unclassifiable, in Classification of Pediatric Myeloproliferative Disorders. *J Pediatr Hematol Oncol* 2006; 28: 700-701.
11. Razzaqi F, Burnside W, **Yu L**, and Cui Y. (2009) Animal Models For Evaluating The Efficacy And Function Of Human Effector Cells In Vivo. In *Targeted Cancer Immune Therapy*. eds. Lustgarten, J., Cui, Y. and Li, S. (**eds**), Springer, pp. 207-223.
12. Shaw P J, Kan F, Ahn KW, Spellman S R, et al **Yu L**, Pulsipher M A. Outcome of Pediatric Bone Marrow Transplantation for Leukemia and Myelodysplasia using Matched Sibling, Mismatched related or Matched Unrelated Donor. *Blood* 2010; 116(9): 4007-4015. PMC2981549.
13. Sencer S F, Zhou T, Freedman L, Ives J A, Chen Z, Wall D, Nieder M, Grupp S, **Yu LC**, Sahdev I, Jonas W B, Wallace JD, Oberbaum M. Traumeel S in preventing and treating mucositis in young patients undergoing SCT: A Report of the Children's Oncology Group. *Bone Marrow Transplant*. 2012 Nov;47(11):1409-14.
14. David Buchbinder, MD, MSHS, Diane J. Nugent, MD, Ruta Brazauskas, PhD, et al , **Yu L C** and Navneet S. Majhail, MD, MS. Late Effects in Hematopoietic Cell Transplant Recipients with Acquired Severe Aplastic Anemia: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant*. 2012 Dec;18(12):1776-84. PMC3496823.
15. Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, Horn B, **Yu L**, Talano JA, Nemecek E, and Chaudhury S. Allogeneic Human Mesenchymal Stem Cell Therapy (remesremcel-L, Prochymal) as Rescue Agent for Severe Refractory Acute GVHD in Pediatric Patients. *Biol Bone Marrow Transplant*. 2013 Nov 8. PMID: In Process.

#### **D. Research Support from 2011 to present**

##### **Ongoing Research Support**

CCT-HPDSC-001 06/01/2007- 05/31/2014

Celgene

Single arm study to assess the safety of transplantation with umbilical cord blood augmented with Human Placental-Derived stem cell (HPDSC) from partially or fully HLA matched related donors in subjects with certain malignant hematologic diseases and non-malignant disorders

Role: Principal Investigator

U58DP003805 (Chen) 09/30/2011-09/29/2014

HHS-CDC

Enhancing Cancer Registries for Early Case Capture of Pediatric and Young Adult

The goal is to enhance registry operations and build sustainable infrastructures for timely pediatric cancer database for the surveillance, clinical, and research communities.

Role: Co-investigator

U54A1082973 08/01/2011- Sept 2014

UCSF/ National Institutes of Health-NIAID

Primary Immune Deficiency Treatment Consortium

The Primary Immune Deficiency (PID) Treatment Consortium (PIDTC) consists of 13 major centers in North America whose shared goal is to improve the outcome of patients with rare, life threatening, inherited disorders of the immune system.

Role: Principal Investigator

Hyundai Hope on Wheels 06/01/2013 – 05/31/2014

The role of myeloid derived suppressor cells in graft vs. host disease in pediatric hematopoietic stem cell transplantation

Role: Co-Investigator

U10CA063845 (Veith)

06/01/2009 – 05/31/2014

LSUHSC Minority-Based Community Clinical Oncology Program

The goal of this project is to increase minority participation in state-of-the-art, NCI clinical trials in the Greater New Orleans area and surrounding regions.

Role: COG PI

**Completed Research Support**

A1501088

Jan 2009 - Dec. 2010

Pfizer

Open-Label, Intravenous to oral switch multiple dose study to evaluate the Pharmacokinetics, safety and tolerability of Voriconazole in immune-compromised adolescents aged 2 to < 12 years who are at high risk for systemic fungal infection

Role: Principal Investigator

Hyundai Wheels of Hope

August 2010-July 2011

Understanding the role of dendritic cells in improving the outcome of Hematopoietic Stem cell transplant.

Role: Co-Investigator

Chimerix Inc

June 2011- Dec 2012

CMX001-202

Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease following Hematopoietic Stem Cell Transplantation (ADV HALT Trial)

Role: Principal Investigator

U10CA98543

Jan. 1, 2010- Apr 31, 2012

COG ANBL0032 Phase III study of Chimeric Antibody 14.18 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

The primary objective of this study is to determine if monoclonal antibody CH14.18 +cytokines+isotretinoin improves event free survival after myeloablative therapy and stem cell rescue as compared to RA alone, in high risk neuroblastoma pts who have achieved a pre-ASCT response of CR, VGPR, or PR.

Role: Principal Investigator